Obstetrics and GynecologyObstetrics and GynecologyАкушерство и гинекология0300-90922412-5679Bionika Media246596ArticlesСтатьиResearch ArticleCOMBINATION HORMONAL CONTRACEPTION: QUESTIONS AND ANSWERSКОМБИНИРОВАННАЯ ГОРМОНАЛЬНАЯ КОНРАЦЕПЦИЯ В ВОПРОСАХ И ОТВЕТАХBOSTANDZHYANL. LБОСТАНДЖЯНЛана Лаврентьевна

канд. мед. наук, науч. сотр. научно-поликлинического отд-ния

l_bostanjian@oparina4.ruPRILEPSKAYAV. NПРИЛЕПСКАЯВ. НAcademician V. I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health and Social Development of RussiaФГУ Научный центр акушерства, гинекологии и перинатологии им. академика В.И. Кулакова Минздравсоцразвития России150520115NO5 (2011)№5 (2011)12913317022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/0300-9092/article/view/246596

The review of world literature has shown that there are currently unavailable scientifically founded data suggesting that it is necessary to discontinue the use of combined oral contraceptives (COC) every several years. On the contrary, the present-day specialists’ viewpoint that it is possible and necessary to use COC without interruption so long as there is a need for contraception is quite valid.

Обзор мировой литературы показал, что в настоящее время нет никаких научно обоснованных данных, указывающих на необходимость прерывания приема комбинированных оральных контрацептивов (КОК) каждые несколько лет. Напротив, вполне правомерна точка зрения современных специалистов о возможности и необходимости приема КОК без перерывов так долго, пока существует потребность в контрацепции.

interruptions in COC usenoncontraceptive effects of COCrisk for cancervenous thrombophiliaперерывы в приеме КОКнеконтрацептивные эффекты КОКриск развития онкологических заболеванийвенозная тромбоэмболияСеров В.Н., Прилепская В.Н., Овсянникова Т.В. Гинекологическая эндокринология. — М., 2006. — C. 252—284.Barnhart K.T., Schreiber C.A. Return to fertility following discontinuation of oral contraceptives // Fertil End Steril. — 2009. — Vol. 91, № 3. — P. 659—663.Bianchi-Demicheli F., Ludicke F., Campana A. Premenstrual dysphoric disorder: approach and treatment// Gynecol. Obstet. Fertil. — 2003. — Vol. 31, № 1. — P. 49—54.Braendle W., Kuhl H., Mueck A. et al. Does hormonal contraception increase the risk for tumors? // Ther. Umsch. — 2009. — Vol. 66, № 2. — P. 129—135.Burkman R.T., Collins J.A., Shulman L.P. et al. Current perspectives on oral contraceptive use// Am. J. Obstet. Gynecol. — 2001. — Vol. 185. — P. 4—12.Dinger J.C., Heinemann L.A., Kühl-Habich D. The safety of a drospirenon-containig oral contraceptive: final results from the European Active Surveillance study on oral contraceptives based on 142, 475 women-years of observation// Contraception. — 2007. — Vol. 75, № 5. — P. 344—354.Farrow A., Hull M.G.R., Northstone K. et al. Prolonged use of oral contraception before a planned pregnancy is associated with a decreased risk of delayed conception // Hum. Reprod. — 2002. — Vol. 17, № 10. — P. 2754—2761.Fernandez E., La Vecchia C., Balducci A. et al. Oral contraceptives and colorectal cancer risk: a meta-analysis// Br. J. Cancer. — 2001. — Vol. 84, № 5. — P. 722—727.Folger S.G., Marchbanks P.A., McDonald J.A. et al. Risk of breast cancer associated with short-term use of oral contraceptives// Cancer Causes Control. — 2007. — Vol. 18. — P. 189—198.Glasier A., Shields W.C. Can we improve contraceptive use?// Contraсeption. — 2006. — Vol. 73, № 1. — P. 1—3.Huber L.R., Hogue C.J., Drews C., et al. Contraceptive use and discontinuation : findings from the contraceptive history, initiation, and choice study//Am. J. Obstet. Gynecol. — 2006. — Vol.194, № 5. — P. 1290—1295.Hunter D.J., Colditz G.A., Hankinson S.E. et al. Oral contraceptive use and breast cancer: a prospective study of young women// Cancer Epidemiol. Biomarkers Prev. — 2010. — Vol. 19, № 10. — Р. 2496—2502.Khader Y.S., Rice J., John L. et al. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis// Contraception. — 2003. — Vol. 68. — P. 11—17.Kuohung W., Borgatta L., Stubblefield Ph. Low-dose oral contraceptives and bone mineral density: An evidence-based analysis// Contraception. — 2000. — Vol. 61, № 2. — P. 77—82.Lech M.M., Ostrowska L. Risk of cancer development in relation to oral contraception// Eur. J. Contrasept. Reprod. Hlth Care. — 2006. — Vol. 11, № 3. — P. 162—168.Lidegaard O., Lokkegaard E., Svendsen A.L. et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study// Br. Med. J. — 2009. — Vol. 339. — Р. 2890.Lloyd T., Taylor D.S., Lin H.M. et al. Oral contraceptive use by teenage women does not affect peak bone mass: a longitudinal study//Fertil and Steril. — 2000. — Vol. 74. — P. 734—738.Marchbanks P.A., McDonald J.A., Wilson H.G. et al. Oral contraceptives and the risk of the breast cancer// N. Engl. J. Med. — 2002. — Vol. 346. — P. 2025—2032.Moreau C., Cleland K., Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States// Contraception. — 2007. — Vol. 76, № 4. — P. 267—272.Mueck A.O., Seeger H., Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review// Endocrinol. Relat. Cancer. - 2010. - Vol. 23, № 17. — Р. 263—271.Oelkers W. Antimineralcorticoid activity of a novel oral contraceptive containing drospirenon, a unique progestogen resembling natural progesterone//Eur. J. Contracept. Reprod. Hlth Care. — 2002. — Vol. 7, suppl. 3. — P. 19—26.Pearlstein T.B., Bachmann G.A., Zacur H.A. et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation// Contraception. — 2005. — Vol. 72. — P. 414—421.Pymar H.C., Creinin M.D. The risks of oral contraceptive pills// Semin. Reprod. Med. — 2001. — Vol. 19. — P. 305312.Reed S.D., Scholes A.Z., LaCroix L.E. et al. Longitudinal changes in bone density in relation to oral contraceptive use// Contraception. — 2003. — Vol. 68. — P. 177-182.Spitzer W.O., Faith J.M., Macrae K.D. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies// Hum. Reprod. — 2002. — Vol. 17. — P. 2307—2314.Vaughan B., Trussel J., Kost K. et al. Discontinuation and resumption of contraceptive use: results from the 2002 Natiional Survey of family Growth // Contraception. - 2008. — Vol. 78, № 4. — P. 271—283.Waesthoff C.L., Heartwell S., Edwards S. et al. Oral contraceptive discontinuation: do side effects matter?// Am. J. Obstet. Gynecol. - 2007. — Vol. 196, № 4. — Р. 412.Yonkers K.A., Brown C., Pearlstein T.B. et al. Efficacy of a new low-dose oral contraceptive with drospirenon in premenstrual dysphoric disorder// Obstet. Gynecol. — 2005. — Vol. 106, № 3. — P. 492—501.